These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19508488)

  • 1. Seborrhoeic keratoses appearing in sites of previous psoriasis plaques during treatment with efalizumab.
    Vestergaard ME; Kossard S; Murrell DF
    Clin Exp Dermatol; 2009 Dec; 34(8):e564-6. PubMed ID: 19508488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient eruptive seborrheic keratoses associated with erythrodermic psoriasis and erythrodermic drug eruption: report of two cases.
    Flugman SL; McClain SA; Clark RA
    J Am Acad Dermatol; 2001 Dec; 45(6 Suppl):S212-4. PubMed ID: 11712062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
    Toth DP; Papp K; Gratton D
    Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ; Scherschun L
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced inflammatory seborrheic keratoses in a man with acute myeloid leukemia: a variant of Leser-Trélat sign?
    Lilly E; Granter SR; Haynes HA; Ibrahimi OA
    Cutis; 2012 Nov; 90(5):235-6. PubMed ID: 23270192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
    Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
    Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 532-nm diode laser treatment of seborrheic keratoses with color enhancement.
    Culbertson GR
    Dermatol Surg; 2008 Apr; 34(4):525-8; discussion 528. PubMed ID: 18248487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency?
    Yeatman JM; Kilkenny M; Marks R
    Br J Dermatol; 1997 Sep; 137(3):411-4. PubMed ID: 9349339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
    Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
    Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superficial spreading (and disappearing) seborrheic keratosis.
    Winkelmann RK
    Cutis; 1999 Apr; 63(4):235-7. PubMed ID: 10228754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.